Journal of Nephrology & Renal DiseasesISSN: 2576-3962

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Outcomes of Mammalian Target of Rapamycin Inhibitor Regimens in Kidney Transplant Recipients with Pre-Transplant Primary Diagnosis of Hypertension and Other Etiologies: An Observational Study

Objective: We aimed to examine the outcomes associated with the mammalian target of rapamycin inhibitor (sirolimus or everolimus), (m-TORi) regimens in kidney transplant recipients (KTR) with primary diagnoses of hypertension.

Methods: In this retrospective observational study, 187,381 adult KTRs were classified into the hypertension or non-hypertension cohort based on their primary renal diagnosis pre-transplant. Cox regressions were used to analyze the risks for death and graft loss associated with the following regimens: m-TORi with or without steroids combined with cyclosporine (m-TORi+CSA), mycophenolate (m-TORi+MPA) or tacrolimus (m-TORi+Tac); cyclosporine with or without steroids combined with mycophenolate (CSA+MPA); and other regimens.

Results: The risk of death-with-graft-function did not differ between mTORi regimens in KTRs with a primary diagnosis of HTN [mTORi+CSA vs: mTORi+MPA (HR=0.88; 95% CI=0.68-1.14) and mTORi+Tac (HR=1.16; 95% CI=0.91-1.47); and mTORi+MPA vs. mTORi+Tac (HR=1.31; 95% CI=1.00-1.72)]. However, in KTRs with a primary diagnosis other than HTN, mTORi+CSA is associated with a lower risk of death-with-graft-function than mTORi+MPA or mTORi+Tac [mTORi+CSA vs. mTORi+MPA: HR=0.81; 95% CI=0.71-0.92] and [mTORi+CSA vs. mTORi+Tac: HR=0.76; 95% CI=0.66-0.87]. In both primary diagnosis cohorts, the risks of overall and death-censored graft loss are higher with m-TORi+MPA than the other m-TORi regimens.

Conclusion: MTORi+MPA is associated with higher risks of graft loss regardless of pre-transplant primary diagnosis. MTORi+CSA is associated with a higher likelihood of survival with a functioning graft in KTRs with a non-HTN primary diagnosis, a benefit not seen among KTRs with a primary diagnosis of HTN. Therefore, outcomes associated with mTORi regimens vary with the pre-transplant primary diagnosis classification of hypertension or non-hypertension: these associations may be considered in mTORi regimen selection after kidney transplantation.

Special Features

Full Text


Track Your Manuscript

Media Partners